These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 34425853)

  • 21. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
    Ferreira M; Swalduz A; Greillier L; du Rusquec P; Curcio H; Raimbourg J; Toffart AC; Gounant V; Couraud S; De Chabot G; Friard S; Hureaux J; Jeannin G; Odier L; Ricordel C; Wislez M; Descarpentries C; Herbreteau G; Missy P; Morin F; Westeel V; Cortot AB
    Lung Cancer; 2024 Oct; 196():107934. PubMed ID: 39277916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
    Li X; Lu Y; Zhao J; Yu Y; Tian H; Zhu H; Li W; Xia Y; Chen L
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):395. PubMed ID: 39180576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
    Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
    Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
    Future Oncol; 2024; 20(22):1553-1563. PubMed ID: 38629593
    [No Abstract]   [Full Text] [Related]  

  • 27. Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape.
    Simard MA; Cabrera-Galvez C; Viteri S; Geist F; Reischmann N; Zühlsdorf M; Karachaliou N
    Neoplasia; 2024 Nov; 57():101063. PubMed ID: 39366215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tepotinib hydrochloride for the treatment of non-small cell lung cancer.
    Wu ZX; Li J; Dong S; Lin L; Zou C; Chen ZS
    Drugs Today (Barc); 2021 Apr; 57(4):265-275. PubMed ID: 33851690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Fujino T; Suda K; Mitsudomi T
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of
    Subramanian J; Tawfik O
    Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
    [No Abstract]   [Full Text] [Related]  

  • 32. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 33. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
    Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
    Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
    Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
    Basse C; Régaldo-Saint Blancard L
    Bull Cancer; 2023 Sep; 110(9):869-871. PubMed ID: 37442707
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a
    Conci N; Marchiori V; Federico AD; Giglio A; Sperandi F; Melotti B; Gelsomino F
    Per Med; 2024; 21(4):205-209. PubMed ID: 38958204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Kato T; Yang JC; Ahn MJ; Sakai H; Morise M; Chen YM; Han JY; Yang JJ; Zhao J; Hsia TC; Berghoff K; Bruns R; Vioix H; Lang S; Johne A; Le X; Paik PK
    Br J Cancer; 2024 Jun; 130(10):1679-1686. PubMed ID: 38575731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
    Deng HY; Qiu XM; Zhu DX; Tang XJ; Zhou Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4623-4628. PubMed ID: 36171456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.